65,437 trials
Estrogen Receptor-positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Cancer
Primary: Number of Participants With Grade 4 Toxicity
Non Small Cell Lung Cancer
Primary: Disease Control Rate (DCR) — 63.3 percentage of participants
HIV · Sexually Transmitted Diseases
Primary: 6-item Self-report of Program Acceptability — 84; 94; 101; 60 Participants
HIV-1 Infection
Primary: GEN Phase: Percentage of Participants Experiencing Treatment-Emergent Grade 3 or Higher Adverse Events Up to Week 48 — 32.7 percentage of participants
Alzheimer's Disease
Primary: Brain Glucose Consumption — 27.9; 28.1 umol/100 g/min
Metastatic Renal Cell Cancer
Primary: Recommended Dose for Phase 2 Studies of LY573636-Sodium Combined With Sunitinib in Participants With Metastatic Renal Cell Carcinoma — NA; NA; NA; NA micrograms per…
Dental Plaque
Primary: Mean Change From Baseline (Pre-brushing to Post-brushing) in Turesky Score After Single Supervised Use (Test Product 1 Versus [vs] Test Product 4) After 4 Weeks — 2.90…
Kidney Failure, Acute · Renal Replacement Therapy
Primary: Number of Participants Who Developed Acute Kidney Injury Within 72 Hours — 17; 14 Participants
Multiple Myeloma
Primary: Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria — 0.0 percentage of participants
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Percentage of Patients With Objective Tumor Response Rate (Either Complete Response (CR) or Partial Response (PR) Using RECIST Version 1.0 — 8 Percentage of participants
Type 2 Diabetes Mellitus
Primary: Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events — 5; 3; 3; 5 participants
Herpes Zoster
Primary: Change in the Short Form 36-item-health Survey (SF36) Physical Functioning (PF) From Baseline Score to Mean Score After First Dose — 1.9 Score units
Advanced Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) in Intermediate/Poor Risk Participants Per Independent Radiology Review Committee (IRRC) Using RECIST v1.1 — 41.6; 26.5 percentage of…
Rheumatoid Arthritis
Primary: Percentage of Subjects That Withdrew Due to a Treatment-emergent Adverse Event (TEAE) — 2.1; 1.6 percentage of participants
Major Depressive Disorder · Nicotine Dependence · Depression
Primary: Number of Participants Achieving Smoking Abstinence — 24; 18 Participants